We are live on ! Find out more
SGA

Sector Gamma AS Portfolio holdings

AUM $423M
1-Year Est. Return 17.56%
This Fund
S&P 500
This Quarter Est. Return
-1.23%
1 Year Est. Return
+17.56%
3 Year Est. Return
+28.73%
5 Year Est. Return
+52.48%
10 Year Est. Return
+238.19%
AUM
$423M
AUM Growth
-$15.2M
Cap. Flow
-$6.93M
Cap. Flow %
-1.64%
Top 10 Hldgs %
54.1%
Holding
47
New
11
Increased
12
Reduced
16
Closed
5

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$10.9M
2
ABT icon
Abbott
ABT
+$9.88M
3
IQV icon
IQVIA
IQV
+$7.85M
4
QGEN icon
Qiagen
QGEN
+$7.68M
5
PFE icon
Pfizer
PFE
+$6.17M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$17.2M
2
TMO icon
Thermo Fisher Scientific
TMO
+$12.6M
3
MRK icon
Merck
MRK
+$11.9M
4
BDX icon
Becton Dickinson
BDX
+$9.14M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.53M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNC icon
26
Centene
CNC
$32.8B
$5.32M 1.26%
162,405
-95,704
-37% -$3.92M
TNDM icon
27
Tandem Diabetes Care
TNDM
$1.17B
$5.12M 1.21%
267,091
– –
PTCT icon
28
PTC Therapeutics
PTCT
$6.52B
$5.11M 1.21%
75,000
+13,077
+21% +$926K
LH icon
29
Labcorp
LH
$23.2B
$5.07M 1.2%
19,019
-8,000
-30% -$2.17M
ASND icon
30
Ascendis Pharma A/S
ASND
$17.1B
$4.87M 1.15%
21,305
+5,000
+31% +$1.12M
EW icon
31
Edwards Lifesciences
EW
$49.4B
$4.84M 1.14%
60,402
-36,000
-37% -$2.97M
DXCM icon
32
DexCom
DXCM
$29.6B
$3.52M 0.83%
56,122
-20,000
-26% -$1.39M
CRNX icon
33
Crinetics Pharmaceuticals
CRNX
$8.88B
$3.42M 0.81%
94,195
-20,805
-18% -$929K
KURA icon
34
Kura Oncology
KURA
$964M
$3.35M 0.79%
411,810
-44,031
-10% -$378K
HUM icon
35
Humana
HUM
$48B
$3.33M 0.79%
+19,202
New +$3.94M
BBIO icon
36
BridgeBio Pharma
BBIO
$15.9B
$3.29M 0.78%
+44,263
New +$3.21M
IOVA icon
37
Iovance Biotherapeutics
IOVA
$2.23B
$3.16M 0.75%
+900,000
New +$2.88M
DNLI icon
38
Denali Therapeutics
DNLI
$3.7B
$3.12M 0.74%
+162,710
New +$3.24M
ARDX icon
39
Ardelyx
ARDX
$1.28B
$3.09M 0.73%
+516,131
New +$3.41M
COGT icon
40
Cogent Biosciences
COGT
$6.68B
$3.08M 0.73%
+80,000
New +$2.95M
OGN icon
41
Organon & Co
OGN
$3.55B
$2.25M 0.53%
375,974
+75,974
+25% +$572K
ARWR icon
42
Arrowhead Research
ARWR
$10.5B
$1.88M 0.44%
+30,000
New +$1.9M
CERT icon
43
Certara
CERT
$1.08B
– –
-230,565
Closed -$2.03M
CGON icon
44
CG Oncology
CGON
$6.34B
– –
-52,039
Closed -$2.16M
HCA icon
45
HCA Healthcare
HCA
$82.3B
– –
-10,784
Closed -$5.03M
REGN icon
46
Regeneron Pharmaceuticals
REGN
$70.9B
– –
-7,165
Closed -$5.53M
TMO icon
47
Thermo Fisher Scientific
TMO
$198B
– –
-21,688
Closed -$12.6M
1
2

Similar funds

AFWM
AMJ Financial Wealth Management Leesburg, Virginia $424M AUM 37.24% 1-Year Est. Return
MP
McDonald Partners Cleveland, Ohio $424M AUM 29.07% 1-Year Est. Return
DS
Dalal Street West Lake Hills, Texas $423M AUM 115.19% 1-Year Est. Return
RS
Retirement Solution Redmond, Washington $423M AUM 16.83% 1-Year Est. Return
DF
Dunhill Financial London, United Kingdom $424M AUM 16.79% 1-Year Est. Return
OGM
OnyxPoint Global Management New York $424M AUM 84.95% 1-Year Est. Return
CPIM
Cypress Point Investment Management Mill Valley, California $424M AUM
MPPLM
Midwest Professional Planners Ltd (MPPL) Wausau, Wisconsin $425M AUM 28.89% 1-Year Est. Return

Sector Gamma AS's Q1 2026 Portfolio in Review

As of Q1 2026, Sector Gamma AS held 47 positions worth $423M, down 3.5% from $439M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sector Gamma AS's Q1 2026 filing shows 11 new, 12 increased, 16 reduced and 5 closed positions. Its largest new stake was UnitedHealth: 36,435 shares worth $9.86M. The largest sale was Gilead Sciences, an estimated $17.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sector Gamma AS's largest Q1 2026 buy was UnitedHealth: 36,435 shares worth $9.86M.
  • Sector Gamma AS added most to Pfizer in Q1 2026, an estimated $6.17M increase.
  • Sector Gamma AS's biggest Q1 2026 reduction was Gilead Sciences, cutting an estimated $17.2M.
  • Sector Gamma AS fully exited Thermo Fisher Scientific in Q1 2026, selling an estimated $12.6M.
  • Sector Gamma AS's ten largest holdings make up 54% of its $423M portfolio in Q1 2026.
  • Sector Gamma AS opened 11 new positions and closed 5 in Q1 2026.
  • Sector Gamma AS's portfolio value fell 3.5% quarter-over-quarter to $423M.

Based on Sector Gamma AS's 13F filing for Q1 2026, filed 7 May 2026.